In a Phase II randomized study, Masotti et al. found that preoperative administration of recombinant human IL-2 (rhIL-2) increased CD8+ T cell, T helper cell, and NK cell numbers in NSCLC patients (237). The gene discussed is IL2; the disease is non-small cell lung carcinoma.